title: [Molecular diagnosis and response prediction to anti-tyrosine kinase receptors in oncology].
abstract: Tyrosine kinase receptors are an important family of membrane receptors implicated in oncogenesis. Their activation triggers signaling cascades that activate cell growth, proliferation and controls cell death. Inhibiting these receptors leads to signaling impairments and favors antitumor activity. Different anti-receptor tyrosine kinases are proposed for therapy, mainly consisting in monoclonal antibodies impairing the fixation of ligands onto the receptors, and of tyrosine kinase inhibitors, blocking the phosphorylation of the receptors. These therapeutic agents are being extensively studied and supported by considerable scientific and financial investments in the pharmaceutical industry. In this paper, we will consider Human Epidermal Growth Factor Receptors (HERs). Therapeutic use of targeted therapy agents, directed against these receptors is conditioned by the detection of target receptor expression in the tumor tissues. However, it appears more and more clearly that additional diagnosis molecular markers as well as surrogate response prediction markers are needed to enable more efficacious therapeutics.
authors.affiliation: Biologie Cellulaire Oncologique, Faculté de pharmacie, 5 Rue A Lebrun, F 54001 Nancy. jean-louis.merlin@pharma.uhp-nancy.fr
authors.forename: J-L
authors.initials: JL
authors.lastname: Merlin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D066246:ErbB Receptors / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases